Creation of 100 new jobs by global human data sciences innovator

DUBLIN - 22 February 2019 IQVIA (“IQVIA”) (NYSE: IQV), a leading global provider of information, innovative technology solutions and contract research services, today announces the creation of 100 jobs in Dublin, Ireland.
The new roles at IQVIA’s Dublin East Point Campus will consist of highly skilled, full-time jobs in the areas of Clinical Project Management, Data Management, Drug Safety and Biostatistics. In particular, IQVIA is recruiting Pharmacovigilance specialists, across a variety of safety services spanning both clinical trials and medicines safety. There will also be a number of opportunities available for life science graduates. Recruitment is underway and IQVIA expects the roles to be filled in the first half of 2019.
In Ireland since 1990, IQVIA (formerly IMS Health and Quintiles) has been a clinical research pioneer for the pharmaceutical industry. The additional roles will increase IQVIA’s capability to serve its customers across Europe and the world. In addition to supporting its global operations, IQVIA’s activities in Ireland include: tracking the pharmaceutical market, conducting market research, providing consulting services across the healthcare spectrum, and offering contract resources to support healthcare companies commercialise their innovative medicines.
Martin Giblin, SVP, Global Head, Centralized Monitoring Services, Country Head IQVIA Ireland, commented “Ireland is a strategically important location for IQVIA, and today’s announcement represents a significant step in increasing our capability to serve our pharma customers across Europe and the world. Ireland has a rich base of life sciences talent, is a great place to do business and we look forward to continuing to grow our business here.”
Minister for Finance, Public Expenditure and Reform, Paschal Donohoe TD, said “Ireland’s pharma industry continues to grow and today’s announcement by IQVIA is another exciting development. Ireland’s ability to retain companies such as IQVIA is a testament to our attractive business environment, robust regulatory framework, and skilled labour force. We are delighted to see an industry leader that supports the pharma and life science sector continuing its expansion, which will enable IQVIA to serve more customers with their innovative technology around the world.”
Tommy Fanning, Head of Biopharmaceuticals, IDA Ireland, said“We are delighted with today’s announcement as it is a vote of confidence in Ireland and adds significantly to the expert cluster in biopharma and clinical research. IQVIA’s decision to build on its existing strong presence provides high quality challenging jobs which fit well with the future of the life sciences sector in Ireland. IDA will continue to work closely with IQVIA to support the growth of the company’s operations into the future.”

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.
IQVIA’s insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviours and scientific advances, to advance their path toward cures. To learn more, visit